Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
51
BPMUF Quote, Financials, Valuation and Earnings
Last price:
$71.00
Seasonality move
:
3.18%
Day range:
$71.00 - $71.00
52-week range:
$47.50 - $74.00
Dividend yield:
0%
P/E ratio:
19.33x
P/S ratio:
3.46x
P/B ratio:
9.27x
Volume:
--
Avg. volume:
10
1-year change:
34.39%
Market cap:
$871.3M
Revenue:
$279.8M
EPS (TTM):
$3.67
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BPMUF
Basilea Pharmaceutica AG
|
$93.1M | -- | -- | -- | -- |
|
ACIU
AC Immune SA
|
$878.5K | -$0.13 | 11.32% | -18.31% | $9.20 |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -- | -- | -- |
|
ELVAF
EvoNext Holdings SA
|
-- | -- | -- | -- | -- |
|
ONC
BeOne Medicines Ltd.
|
$1.5B | $1.30 | 27.83% | 6689.47% | $409.68 |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BPMUF
Basilea Pharmaceutica AG
|
$71.00 | -- | $871.3M | 19.33x | $0.00 | 0% | 3.46x |
|
ACIU
AC Immune SA
|
$2.84 | $9.20 | $285.7M | -- | $0.00 | 0% | 55.40x |
|
CSBTF
Kuros Biosciences Ltd.
|
$32.00 | -- | $1.3B | -- | $0.00 | 0% | 9.78x |
|
ELVAF
EvoNext Holdings SA
|
$1.1700 | -- | $8.4M | 5.90x | $0.00 | 0% | 0.61x |
|
ONC
BeOne Medicines Ltd.
|
$299.02 | $409.68 | $33.1B | 118.52x | $0.00 | 0% | 6.33x |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
$21.15 | -- | $274.4M | 1.45x | $0.00 | 0% | 4.78x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BPMUF
Basilea Pharmaceutica AG
|
85.07% | 0.818 | -- | 2.96x |
|
ACIU
AC Immune SA
|
6.95% | 3.782 | 2.01% | 1.10x |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -0.557 | -- | 1.61x |
|
ELVAF
EvoNext Holdings SA
|
-- | 0.078 | -- | -- |
|
ONC
BeOne Medicines Ltd.
|
31.44% | 0.327 | 5.95% | 2.98x |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
33% | -7.351 | -- | 0.51x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BPMUF
Basilea Pharmaceutica AG
|
-- | -- | -0.84% | -15.42% | -- | -- |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -6.35% | -6.35% | -- | -- |
|
ELVAF
EvoNext Holdings SA
|
-- | -- | -- | -- | -- | -- |
|
ONC
BeOne Medicines Ltd.
|
$1.3B | $185.8M | 5.51% | 7.54% | 12.35% | $381.2M |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
-- | -- | 123.12% | 276.68% | -- | -- |
Basilea Pharmaceutica AG vs. Competitors
-
Which has Higher Returns BPMUF or ACIU?
AC Immune SA has a net margin of -- compared to Basilea Pharmaceutica AG's net margin of -1688.87%. Basilea Pharmaceutica AG's return on equity of -15.42% beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital BPMUFBasilea Pharmaceutica AG-- -- $125.1M ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About BPMUF or ACIU?
Basilea Pharmaceutica AG has a consensus price target of --, signalling downside risk potential of --. On the other hand AC Immune SA has an analysts' consensus of $9.20 which suggests that it could grow by 223.77%. Given that AC Immune SA has higher upside potential than Basilea Pharmaceutica AG, analysts believe AC Immune SA is more attractive than Basilea Pharmaceutica AG.
Company Buy Ratings Hold Ratings Sell Ratings BPMUFBasilea Pharmaceutica AG0 0 0 ACIUAC Immune SA4 0 0 -
Is BPMUF or ACIU More Risky?
Basilea Pharmaceutica AG has a beta of 0.327, which suggesting that the stock is 67.337% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.637, suggesting its more volatile than the S&P 500 by 63.73%.
-
Which is a Better Dividend Stock BPMUF or ACIU?
Basilea Pharmaceutica AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Basilea Pharmaceutica AG pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BPMUF or ACIU?
Basilea Pharmaceutica AG quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $1.2M. Basilea Pharmaceutica AG's net income of -- is lower than AC Immune SA's net income of -$19.8M. Notably, Basilea Pharmaceutica AG's price-to-earnings ratio is 19.33x while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Basilea Pharmaceutica AG is 3.46x versus 55.40x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BPMUFBasilea Pharmaceutica AG3.46x 19.33x -- -- ACIUAC Immune SA55.40x -- $1.2M -$19.8M
-
Which has Higher Returns BPMUF or CSBTF?
Kuros Biosciences Ltd. has a net margin of -- compared to Basilea Pharmaceutica AG's net margin of --. Basilea Pharmaceutica AG's return on equity of -15.42% beat Kuros Biosciences Ltd.'s return on equity of -6.35%.
Company Gross Margin Earnings Per Share Invested Capital BPMUFBasilea Pharmaceutica AG-- -- $125.1M CSBTFKuros Biosciences Ltd.-- -- $65M -
What do Analysts Say About BPMUF or CSBTF?
Basilea Pharmaceutica AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Kuros Biosciences Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Basilea Pharmaceutica AG has higher upside potential than Kuros Biosciences Ltd., analysts believe Basilea Pharmaceutica AG is more attractive than Kuros Biosciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BPMUFBasilea Pharmaceutica AG0 0 0 CSBTFKuros Biosciences Ltd.0 0 0 -
Is BPMUF or CSBTF More Risky?
Basilea Pharmaceutica AG has a beta of 0.327, which suggesting that the stock is 67.337% less volatile than S&P 500. In comparison Kuros Biosciences Ltd. has a beta of 0.916, suggesting its less volatile than the S&P 500 by 8.447%.
-
Which is a Better Dividend Stock BPMUF or CSBTF?
Basilea Pharmaceutica AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kuros Biosciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Basilea Pharmaceutica AG pays -- of its earnings as a dividend. Kuros Biosciences Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BPMUF or CSBTF?
Basilea Pharmaceutica AG quarterly revenues are --, which are smaller than Kuros Biosciences Ltd. quarterly revenues of --. Basilea Pharmaceutica AG's net income of -- is lower than Kuros Biosciences Ltd.'s net income of --. Notably, Basilea Pharmaceutica AG's price-to-earnings ratio is 19.33x while Kuros Biosciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Basilea Pharmaceutica AG is 3.46x versus 9.78x for Kuros Biosciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BPMUFBasilea Pharmaceutica AG3.46x 19.33x -- -- CSBTFKuros Biosciences Ltd.9.78x -- -- --
-
Which has Higher Returns BPMUF or ELVAF?
EvoNext Holdings SA has a net margin of -- compared to Basilea Pharmaceutica AG's net margin of --. Basilea Pharmaceutica AG's return on equity of -15.42% beat EvoNext Holdings SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BPMUFBasilea Pharmaceutica AG-- -- $125.1M ELVAFEvoNext Holdings SA-- -- -- -
What do Analysts Say About BPMUF or ELVAF?
Basilea Pharmaceutica AG has a consensus price target of --, signalling downside risk potential of --. On the other hand EvoNext Holdings SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Basilea Pharmaceutica AG has higher upside potential than EvoNext Holdings SA, analysts believe Basilea Pharmaceutica AG is more attractive than EvoNext Holdings SA.
Company Buy Ratings Hold Ratings Sell Ratings BPMUFBasilea Pharmaceutica AG0 0 0 ELVAFEvoNext Holdings SA0 0 0 -
Is BPMUF or ELVAF More Risky?
Basilea Pharmaceutica AG has a beta of 0.327, which suggesting that the stock is 67.337% less volatile than S&P 500. In comparison EvoNext Holdings SA has a beta of -40.297, suggesting its less volatile than the S&P 500 by 4129.699%.
-
Which is a Better Dividend Stock BPMUF or ELVAF?
Basilea Pharmaceutica AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EvoNext Holdings SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Basilea Pharmaceutica AG pays -- of its earnings as a dividend. EvoNext Holdings SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BPMUF or ELVAF?
Basilea Pharmaceutica AG quarterly revenues are --, which are smaller than EvoNext Holdings SA quarterly revenues of --. Basilea Pharmaceutica AG's net income of -- is lower than EvoNext Holdings SA's net income of --. Notably, Basilea Pharmaceutica AG's price-to-earnings ratio is 19.33x while EvoNext Holdings SA's PE ratio is 5.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Basilea Pharmaceutica AG is 3.46x versus 0.61x for EvoNext Holdings SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BPMUFBasilea Pharmaceutica AG3.46x 19.33x -- -- ELVAFEvoNext Holdings SA0.61x 5.90x -- --
-
Which has Higher Returns BPMUF or ONC?
BeOne Medicines Ltd. has a net margin of -- compared to Basilea Pharmaceutica AG's net margin of 4.44%. Basilea Pharmaceutica AG's return on equity of -15.42% beat BeOne Medicines Ltd.'s return on equity of 7.54%.
Company Gross Margin Earnings Per Share Invested Capital BPMUFBasilea Pharmaceutica AG-- -- $125.1M ONCBeOne Medicines Ltd.88.43% $0.58 $6.4B -
What do Analysts Say About BPMUF or ONC?
Basilea Pharmaceutica AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $409.68 which suggests that it could grow by 37.03%. Given that BeOne Medicines Ltd. has higher upside potential than Basilea Pharmaceutica AG, analysts believe BeOne Medicines Ltd. is more attractive than Basilea Pharmaceutica AG.
Company Buy Ratings Hold Ratings Sell Ratings BPMUFBasilea Pharmaceutica AG0 0 0 ONCBeOne Medicines Ltd.17 0 1 -
Is BPMUF or ONC More Risky?
Basilea Pharmaceutica AG has a beta of 0.327, which suggesting that the stock is 67.337% less volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.532, suggesting its less volatile than the S&P 500 by 46.826%.
-
Which is a Better Dividend Stock BPMUF or ONC?
Basilea Pharmaceutica AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Basilea Pharmaceutica AG pays -- of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BPMUF or ONC?
Basilea Pharmaceutica AG quarterly revenues are --, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.5B. Basilea Pharmaceutica AG's net income of -- is lower than BeOne Medicines Ltd.'s net income of $66.8M. Notably, Basilea Pharmaceutica AG's price-to-earnings ratio is 19.33x while BeOne Medicines Ltd.'s PE ratio is 118.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Basilea Pharmaceutica AG is 3.46x versus 6.33x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BPMUFBasilea Pharmaceutica AG3.46x 19.33x -- -- ONCBeOne Medicines Ltd.6.33x 118.52x $1.5B $66.8M
-
Which has Higher Returns BPMUF or SPHDF?
Santhera Pharmaceuticals Holding AG has a net margin of -- compared to Basilea Pharmaceutica AG's net margin of --. Basilea Pharmaceutica AG's return on equity of -15.42% beat Santhera Pharmaceuticals Holding AG's return on equity of 276.68%.
Company Gross Margin Earnings Per Share Invested Capital BPMUFBasilea Pharmaceutica AG-- -- $125.1M SPHDFSanthera Pharmaceuticals Holding AG-- -- $79.8M -
What do Analysts Say About BPMUF or SPHDF?
Basilea Pharmaceutica AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Santhera Pharmaceuticals Holding AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Basilea Pharmaceutica AG has higher upside potential than Santhera Pharmaceuticals Holding AG, analysts believe Basilea Pharmaceutica AG is more attractive than Santhera Pharmaceuticals Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings BPMUFBasilea Pharmaceutica AG0 0 0 SPHDFSanthera Pharmaceuticals Holding AG0 0 0 -
Is BPMUF or SPHDF More Risky?
Basilea Pharmaceutica AG has a beta of 0.327, which suggesting that the stock is 67.337% less volatile than S&P 500. In comparison Santhera Pharmaceuticals Holding AG has a beta of -0.872, suggesting its less volatile than the S&P 500 by 187.184%.
-
Which is a Better Dividend Stock BPMUF or SPHDF?
Basilea Pharmaceutica AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Santhera Pharmaceuticals Holding AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Basilea Pharmaceutica AG pays -- of its earnings as a dividend. Santhera Pharmaceuticals Holding AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BPMUF or SPHDF?
Basilea Pharmaceutica AG quarterly revenues are --, which are smaller than Santhera Pharmaceuticals Holding AG quarterly revenues of --. Basilea Pharmaceutica AG's net income of -- is lower than Santhera Pharmaceuticals Holding AG's net income of --. Notably, Basilea Pharmaceutica AG's price-to-earnings ratio is 19.33x while Santhera Pharmaceuticals Holding AG's PE ratio is 1.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Basilea Pharmaceutica AG is 3.46x versus 4.78x for Santhera Pharmaceuticals Holding AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BPMUFBasilea Pharmaceutica AG3.46x 19.33x -- -- SPHDFSanthera Pharmaceuticals Holding AG4.78x 1.45x -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
93
NBTX alert for Mar 5
Nanobiotix SA [NBTX] is down 5.4% over the past day.
Sell
45
MRNA alert for Mar 5
Moderna, Inc. [MRNA] is down 8.3% over the past day.
Buy
77
SSRM alert for Mar 5
SSR Mining, Inc. [SSRM] is down 7.49% over the past day.
